Patents by Inventor Kevin William Moore

Kevin William Moore has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Precursor compounds to substituted 1,2,4-triazolo[3,4,-a]phathalazine GABA alpha 5 ligands
    Patent number: 6310203
    Abstract: Substituted 1,2,4-Triazolo[3,4-A]phthalazine derivatives that are GABA Alpha 5 ligands are prepared from compounds represented by the formula: in which R1 is hydrogen, halogen, CF3, OCF3, CN or an optionally substituted C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, C2-4alkenyloxy or C2-4alkynyloxy group; R2 is hydrogen, halogen, CF3, OCF3, CN or an optionally substituted C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, C2-4alkenyloxy or C2-4alkynyloxy group; Z is an optionally substituted 5-membered or 6-membered heteroaromatic ring; and G is a leaving group.
    Type: Grant
    Filed: April 11, 2000
    Date of Patent: October 30, 2001
    Assignee: Merck Sharpe & Dohme Limited
    Inventors: William Robert Carling, Tamara Ladduwahetty, Angus Murray MacLeod, Kevin John Merchant, Kevin William Moore, Francine Sternfeld, Leslie Joseph Street
  • Triazolo-pyridazine derivatives as ligands for GABA receptors
    Patent number: 6303597
    Abstract: 1,2,4-triazolo[4,3-b]pyridazine derivatives, possessing an optionally substituted cycloalkyl, phenyl or heteroaryl substituent at the 3-position, a substituted alkoxy moiety at the 6-position, and an optionally substituted bicycloalkyl ring system at the 7-position, are selective ligands for GABAA receptors, in particular having high affinity for the &agr;2 and/or &agr;3 subunit thereof, are useful in the treatment of anxiety and convulsions.
    Type: Grant
    Filed: June 26, 2000
    Date of Patent: October 16, 2001
    Assignee: Merck Sharp & Dohme Limited
    Inventors: William Robert Carling, Kevin William Moore, Leslie Joseph Street
  • Substituted triazolo-pyridazine derivatives as ligands for GABA receptors
    Patent number: 6255305
    Abstract: Substituted triazolo-pyridazine derivative compounds represented by wherein the variables are disclosed herein are selective ligands for GABA-A receptors, particularly for the &agr;2 and/or &agr;3 subunits.
    Type: Grant
    Filed: November 10, 1998
    Date of Patent: July 3, 2001
    Assignee: Merck Sharp & Dohme Limited
    Inventors: Howard Barff Broughton, William Robert Carling, Jose Luis Castro Pineiro, Alexander Richard Guiblin, Andrew Madin, Kevin William Moore, Michael Geoffrey Russell, Leslie Joseph Street
  • Substituted 1,2,4-triazolo[3,4-a]phthalazine derivatives as GABA alpha 5 ligands
    Patent number: 6200975
    Abstract: Substituted 1,2,4-Triazolo[3,4-A]phthalazine derivatives are GABA Alpha 5 ligands and are represented by the formula
    Type: Grant
    Filed: November 12, 1998
    Date of Patent: March 13, 2001
    Assignee: Merck Sharp & Dohme Limited
    Inventors: William Robert Carling, Tamara Ladduwahetty, Angus Murray MacLeod, Kevin John Merchant, Kevin William Moore, Francine Sternfeld, Leslie Joseph Street
  • Five-membered heteroaromatic compounds as dopamine receptor subtype ligands
    Patent number: 5939436
    Abstract: A class of heteroaromatic compounds incorporating a substituted five-membered heteroaromatic nucleus which contains at least two nitrogen atoms are ligands for dopamine receptor subtypes within the body and are therefore useful in the treatment and/or prevention of disorders of the dopamine system, in particular schizophrenia and depression.
    Type: Grant
    Filed: June 25, 1997
    Date of Patent: August 17, 1999
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: William Robert Carling, Paul David Leeson, Kevin William Moore
  • Tetrahydropyridine derivatives as dopamine receptor subtype ligands
    Patent number: 5849765
    Abstract: A class of 1,2,3,6-tetrahydropyridine derivatives, substituted in the 4-position by a fused bicyclic heteroaromatic moiety and in the 1-position by an optionally substituted benzyl moiety, are ligands for dopamine receptor subtypes within the body, in particular the D.sub.4 subtype, and are therefore useful in the treatment and/or prevention of disorders of the dopamine system, in particular schizophrenia or depression.
    Type: Grant
    Filed: March 7, 1997
    Date of Patent: December 15, 1998
    Assignee: Merck Sharp & Dohme, Ltd.
    Inventors: Neil Roy Curtis, Janusz Jozef Kulagowski, Paul David Leeson, Kevin William Moore, Andrew Pate Owens, Martin Richard Teall
  • Imidazolone and oxazolone derivatives as dopamine antagonists
    Patent number: 5698573
    Abstract: A class of imidazolone and oxazolone derivatives of Structure I, ##STR1## wherein X represents oxygen or N--R.sup.1 ;Q represents a substituted five-, six- or seven-membered monocyclic heteroaliphatic ring which contains one nitrogen atom as the sole heteroatom and is linked to the imidazolone or oxazolone ring via a carbon atom;R.sup.1 represents hydrogen or C.sub.1-6 alkyl; andone of R.sup.2 and R.sup.3 represents hydrogen or C.sub.1-6 alkyl and the other of R.sup.2 and R.sup.3 represents cycloalkyl or a group of formula (i), (ii) or (iii): ##STR2## in which Z represents oxygen, sulphur or NH; R.sup.4, R.sup.5 and R.sup.
    Type: Grant
    Filed: March 12, 1996
    Date of Patent: December 16, 1997
    Assignee: Merck, Sharp & Dohme, Ltd.
    Inventors: William Robert Carling, Kevin William Moore